SCHEMBL3140679

SCHEMBL3140679

COc1ccc(N(N)Cc2ccc(Br)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
MAPT P10636 2/20 0.49
RAB9A P51151 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
NPC1 O15118 1/20 0.49
GAA P10253 1/20 0.49
AOC3 Q16853 3/20 0.46
APLNR P35414 1/20 0.44
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
IDO1 P14902 3/20 0.42
AGXT P21549 2/20 0.42
TAAR1 Q96RJ0 1/20 0.42
PYCR1 P32322 1/20 0.41
MAOB P27338 1/20 0.41
ALDH1A1 P00352 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1253767 0.98 MEN1 (0.47) MEN1KMT2AMAPTRAB9AL3MBTL1
SCHEMBL8878400 0.86 PYCR1 (0.44) L3MBTL1MAPK1IDO1TAAR1PYCR1
SCHEMBL12014951 0.85 ACHE (0.52) MAPTAOC3APLNRLMNANPSR1
SCHEMBL9145895 0.83 BCL2A1 (0.55) AOC3APLNRLMNANPSR1IDO1
SCHEMBL12656069 0.83 AOC3 (0.45) AOC3APLNRIDO1AGXTTAAR1
SCHEMBL11052720 0.83 LTA4H (0.53) MEN1KMT2AAOC3APLNRTDP1
SCHEMBL31308090 0.83 MEN1 (0.51) MEN1KMT2AMAPTRAB9AL3MBTL1
SCHEMBL1871474 0.83 LTA4H (0.53) AOC3LMNAMAPK1NPSR1ALDH1A1
Hydrochloric Acid SCHEMBL1395379 0.83 NQO1 (0.42) LMNAMAPK1MAOBALDH1A1TDP1
Hydrochloric Acid SCHEMBL9471980 0.82 TAS2R14 (0.44) MEN1KMT2AMAPTL3MBTL1AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010068311-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR AMIRA PHARMACEUTICALS, INC. (US) 2010-06-17 WO claimed
US-8772495-B2 5-lipoxygenase-activating protein inhibitor PANMIRA PHARMACEUTICALS, LLC (US) 2014-07-08 US disclosed
US-8772495-B2 5-lipoxygenase-activating protein inhibitor PANMIRA PHARMACEUTICALS, LLC (US) 2014-07-08 US disclosed
US-20120220779-A1 Novel Processes GLAXO GROUP LIMITED (GB) 2012-08-30 US disclosed
US-20120220779-A1 Novel Processes GLAXO GROUP LIMITED (GB) 2012-08-30 US disclosed
US-20110160249-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR AMIRA PHARMACEUTICALS, INC. 2011-06-30 US disclosed
US-20110160249-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR AMIRA PHARMACEUTICALS, INC. 2011-06-30 US disclosed
WO-2011054783-A2 NOVEL PROCESSES GLAXO GROUP LIMITED (GB) 2011-05-12 WO disclosed
WO-2010068311-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR AMIRA PHARMACEUTICALS, INC. (US) 2010-06-17 WO disclosed
US-20100075934-A1 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITOR AMIRA PHARMACEUTICALS, INC. (US) 2010-03-25 US disclosed
US-20100075934-A1 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITOR AMIRA PHARMACEUTICALS, INC. (US) 2010-03-25 US disclosed
US-20090291981-A1 5-Lipoxygenase-Activating Protein Inhibitor AMIRA PHARMACEUTICALS, INC. (US) 2009-11-26 US disclosed
US-20090291981-A1 5-Lipoxygenase-Activating Protein Inhibitor AMIRA PHARMACEUTICALS, INC. (US) 2009-11-26 US disclosed
WO-2009055721-A2 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITOR AMIRA PHARMACEUTICALS, INC. (US) 2009-04-30 WO disclosed
WO-1996037469-A1 N-BENZYLINDOL-3-YL PROPANIC ACID DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS MERCK FROSST CANADA INC. (CA) 1996-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075934-A1 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITOR ALOX5, ALOX5AP, LTA4H MEN1 4436/4885KMT2A 3466/4885MAPT 4613/4885
US-20110160249-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR ALOX5, PRMT5, ALOX5AP MEN1 4039/4885KMT2A 401/4885MAPT 4371/4885
US-20120220779-A1 Novel Processes ALOX5, PNPO, ALOX5AP MEN1 4427/4885KMT2A 3971/4885MAPT 4205/4885
US-20090291981-A1 5-Lipoxygenase-Activating Protein Inhibitor ALOX5, LTA4H, ALOX5AP MEN1 4560/4885KMT2A 3058/4885MAPT 4693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.